Australia: Commonwealth damages claim for overpaying on patented products continues

Last Updated: 26 January 2016
Article by Katrina Crooks

The Full Court of the Federal Court of Australia has rejected an argument that the Commonwealth is precluded by provisions of the Therapeutic Goods Act 1989 (Cth) from seeking damages pursuant to undertakings given by two patentees when obtaining interlocutory relief preventing the launch of generic pharmaceutical products. The Commonwealth's claims, in one case including a claim for AU$54.8 million, continues.

Key Points

  • Sections 26B-D of the Therapeutic Goods Act require generic pharmaceutical suppliers to provide certain certificates relating to relevant patents when applying for registration of therapeutic goods and relying on another party's data to support the application. The owners of the relevant patents may then also be required to provide certain certificates if commencing legal action for patent infringement. The provisions also provide for the Commonwealth to recover damages/a pecuniary penalty in certain circumstances, effectively where the relevant party has engaged in misconduct in connection with such legal action.
  • The above provisions were found by the Full Court not to preclude a claim by the Commonwealth for damages pursuant to an undertaking as to damages given by a patentee when an interlocutory injunction is granted in patent infringement proceedings. Importantly in the present cases, this includes situations where there is no allegation of misconduct against the patentee.
  • The Commonwealth will now continue with its claim but must now prove its case for damages.

In the run up to the end of 2015, the Full Court of the Federal Court of Australia handed down its decision in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis) [2015] FCAFC 172. The Court considered an issue arising in two separate proceedings brought by the Commonwealth, one against Sanofi and one against Wyeth. In each case, the Commonwealth sought damages for additional costs allegedly incurred as the result of interlocutory injunctions which prevented the marketing of certain generic products alleged to infringe Sanofi and Wyeth's respective patents.

In patent infringement cases, the patentee may seek an interlocutory injunction prohibiting marketing of a product alleged to infringe the relevant patent(s) pending the final outcome in the case. In such circumstances the patentee will generally be required to give an undertaking to abide by any order of the Court awarding damages to a party adversely affected by the interlocutory injunction, if the infringement claim is unsuccessful at the final hearing. In the cases at hand, Sanofi had obtained interlocutory relief preventing Apotex from supplying products alleged to infringe its clopidogrel bisulphate patent. Similarly Wyeth had obtained interlocutory relief against three generic parties preventing supply of certain venlafaxine products. In each case, the patentee had given the usual undertaking as to damages. Ultimately, the relevant claims of the patents in each case were found invalid such that the infringement actions failed.

The Commonwealth brought proceedings in each case seeking compensation pursuant to the undertakings as to damages. It alleges it has suffered loss as a result of the injunctions, being the difference between the actual reimbursed price for the patented products under the Pharmaceutical Benefits Scheme (PBS) and the price which would have applied if the generic products had been launched. In particular, in the Sanofi case, the claim includes an amount of AU$54.8 million in respect of an initial 12.5% statutory price reduction which the Commonwealth alleges would have been triggered if Apotex's products had been listed on the PBS at the relevant date.

In this context, the Full Court considered a preliminary issue raised in both proceedings as to whether it was open to the Commonwealth to bring such a claim in light of sections 26B-D of the Therapeutic Goods Act 1989.

These provisions were enacted in response to Australia's entry into the Australia-United States Free Trade Agreement of 2004 which required Australia to provide measures in its marketing approval process to prevent a generic supplier 'piggybacking' on clinical data for an originator product, where the product was still covered by a patent. They require a generic supplier seeking to use such data to provide a certificate stating that they do not believe they are marketing a product which would infringe a valid claim of a granted patent, or that they have given the patentee notice of the application for registration of the relevant goods. Where such a certificate is given by the generic party, the originator party must then also provide a certificate if intending to issue proceedings for patent infringement against that generic party, certifying that the proceedings are to be commenced in good faith, have reasonable prospects of success and will be conducted without unreasonable delay. A penalty may be payable to the Commonwealth if such a certificate is found to be misleading, and in certain circumstances where an application for interlocutory relief is sought, and the applicant engages in conduct tantamount to abuse of process, the Court may award compensation to the Commonwealth.

Sanofi and Wyeth each relied on legal authorities holding that statutory rights which are inconsistent with a common law right can displace that common law right. They argued that the relevant provisions of the Therapeutic Goods Act set out a prescriptive scheme which restricted recovery of damages by the Commonwealth to circumstances where the patentee had engaged in the kind of misconduct described. Outside of such cases the Commonwealth could not call upon the usual undertaking as to damages.

The Court did not agree with Sanofi and Wyeth. It found that, rather than restricting the Commonwealth's ability to claim damages, the relevant provisions of the Therapeutic Goods Act provide the Commonwealth with a monetary remedy that would not be available under the usual undertaking as to damages. There was no inconsistency between the relevant provisions and the usual undertaking as to damages. There was also nothing in the Australia-US Free Trade Agreement or any other aspect of the legislative history to suggest that the intention was to curtail the right of the Commonwealth to recover on the usual undertaking as to damages.

Following the decision the Commonwealth's claims will continue. If damages are ultimately awarded to the Commonwealth, this will clearly be of concern to originator companies considering applications for interlocutory injunctions. As the figures cited in this judgment make clear, compensation sought by the Commonwealth on an undertaking as to damages may not be insubstantial.

Shelston IP will keep you updated with further developments in these cases.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Katrina Crooks
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.